Reduction in carboplatin hematopoietic toxicity in tumor bearing mice: Comparative mechanisms and effects of interleukin-1β and corticosteroids

Cancer Biotherapy and Radiopharmaceuticals

Volumn 12, Issue 2, 1997, Pages 101-109

  Rinehart, John J ^a   Keville, Lisa R ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

Carboplatin; Corticosteroids; Hematopoiesis; Interleukin 1 ; Toxicity

Indexed keywords

CARBOPLATIN; CORTICOSTEROID; CORTISONE; CORTISONE ACETATE; INTERLEUKIN 1BETA; THYMIDINE; TRITIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD TOXICITY; COLONY FORMING UNIT GM; CONTROLLED STUDY; DRUG MEGADOSE; DRUG RESISTANCE; FEMALE; FIBROSARCOMA; GRANULOCYTOPENIA; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; MOUSE; NONHUMAN; PREMEDICATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

EID: 0030821806     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1997.12.101     Document Type: Article

References (19)

1. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995;13:2483.
2. Haioun C, Lepage E, Gisselbrecht Ch, Coiffier B, Bosly A, Dupriez B, Nouvel C, Tilly H, Lederlin P, Biron P, Briere J, Gaulard Ph, Reves F. Autologous bone marrow transplantation (ABMT) versus sequential chemotherapy for aggressive non Hodgkin's lymphoma (NHL) in first complete remission (CR): a study of 542 patients (LNH87-2 Protocol) Blood 1995;86:1816.
3. Hagenbeek A, Guglielmi C, Chauvin F, van der Lely J, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL, Coiffier B, Biron P, Somers R, Philip T. Autologous bone marrow transplantation versus conventional chemotherapy in patients with relapsed diffuse non-Hodgkin's lymphoma. Results from a T. Autologous bone marrow transplantation versus conventional chemotherapy in patients with relapsed diffuse non-Hodgkin's lymphoma Results from a prospective, randomized phase III clinical trial in 216 patients (the Parma study). Blood 1995;86:1817.
4. Attal M, Harousseou JL, Stoppa AM, Sotto JJ, Fuzibet G, Rossi JF, Casassus P, Thyss A, Maisonneuve H, Facon T, Ifrah N, Paven C, Bataille R. High dose therapy in multiple myeloma, final analysis of a prospective randomized study of the "intergroupe francais du myelome" (IFM 90). Blood 1995;86:485.
5. Rinehart JJ, Delamater E, Keville L, Measel J. Corticosteroid modulation of Interleukin-1 hematopoietic effects and toxicity in a murine system. Blood 1994;84:1457
6. Rinehart JJ, Keville L, Measel J, Spiekerman AM. Burke K. Corticosteroid alteration of carboplatin induced hematopoietic toxicity in a murine model Blood 1995;86:4493.
7. Twentyman PR, Brown JM, Gray JW, Franko AJ, Scoles MA, Kallman RF. A new mouse tumor model system (RIF-1) for comparison of end-point studies. J Nati Cancer Inst 1980;64:595.
8. Braunschweiger PG, Johnson CS, Kumar N, Ord V, Furmanski P. Antitumor effects of recombinant human interleukin 1β in RIF-1 and Panc02 solid tumors. Cancer Res 1988;48:6011
9. Nakamura S, Kashimoto S, Kajikawa F, Nakata K. Combination effect of recombinant human interleukin 1β with antitumor drugs on syngeneic tumors in mice. Cancer Res 1991;51:215.
10. Stork L, Barczuk L, Kissinger M, Robinson W Interleukin-1 accelerates murine granulocyte recovery following treatment with cyclophosphamide. Blood 1989;73:938-944.
11. Morikage T, Mizushima Y, Sakamoto K, Yano S. Prevention of fatal infections by recombinant human interleukin 1β in normal and anticancer drug-treated mice. Cancer Res 1990;50:2099.
12. Moore MAS. Does stem cell exhaustion result from combining hematopoietic growth factors with chemotherapy? If so, how do we prevent it? Blood 1992;80:3.
13. Fibbe WE, Falkenburg JHF. Regulation of hematopoiesis by interleukin-1 Biotherapy 1990;2:325.
14. Hestdal K, Jacobsen SEW, Ruscetti FW, Budois CM, Longo DL, Chizzomte R, Oppenhiem JJ, Keller JR. In vivo effect of interleukin-1 β on hematopoiesis: role of colony stimulating factor receptor modulation. Blood 1992;80:2486.
15. Zsebo KM, Yuschenkoff VN, Schiffer S, Chang D, McCall E, Dinarello CA, Brown MA, Altrock B, Bagby GC Jr Vascular endothelial cells and granulopoiesis: interleukin-1 stimulates release of G CSF and GM-CSF. Blood 1988;71:99.
16. Futami H, Jansen R, Macphee MJ, Keller J, Mc-Cormick K, Longo DL, Oppenheim JJ, Ruscetti FW, Wiltrout RH Chemoprotective effects of recombinant human IL-1β in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy. J Immunol 1990;145:4121.
17. 2 protect mice from acutely lethal doses of 5-fluorouracil and doxorubicin. J Exper Med 1994;180:1047.
18. Dunlop DJ, Wright EG, Lorimore S, Graham GJ, Holyoake T, Kerr DJ, Wolpe SD, Pragnell IB. Demonstration of stem cell inhibition and myeloprotective effects of SCI/rhMIP1β in vivo. Blood 1992;79:2221.
19. Broxmeyer HE, Williams DE, Lu L, Cooper S, Anderson SL, Beyer GS, Hoffman R, Rubin BY. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factors and Interferon. J Immunol 1986;12:4487.